Posted by Michael Wonder on 25 Jul 2016
NICE approves Servier’s Lonsurf as third-line cancer therapy
25 July 2016 - The National Institute for Health and Care Excellence has recommended trifluridine/tipiracil as an option for treating metastatic colorectal cancer.
The medicine, marketed by Servier as Lonsurf, is recommended in adults who have received other available therapies, including fluoropyrimidine, oxaliplatin or irinotecan chemotherapy, anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents, or where such therapies are not suitable.
Lonsurf, previously known as TAS-102, is a combination of two drugs; trifluridine is a nucleoside analogue anti-viral drug previously used to treat eye infections, while enzyme-inhibitor tipiracil increases the bioavailability of trifluridine preventing its breakdown.
